Evommune (EVMN) Registration Filing summary

Company overview and business model

• Clinical-stage biotech focused on therapies for chronic inflammatory diseases, with lead programs in chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC).

• Pipeline includes two Phase 2 candidates: EVO756 (oral MRGPRX2 antagonist) and EVO301 (injectable IL-18BP fusion protein).

• Management team has deep immunology and drug development experience, with prior success in developing and commercializing novel therapies.

• Business model includes internal R&D, in-licensing, and strategic collaborations, with a focus on high unmet need indications.

Financial performance and metrics

• Net loss of $66.8M in 2024 and $28.1M for the six months ended June 30, 2025; accumulated deficit of $180.3M as of June 30, 2025.

• Revenue of $7.0M in 2024 and $3.0M for the six months ended June 30, 2025, primarily from license agreements.

• Cash, cash equivalents, and short-term investments of $86.8M as of June 30, 2025; estimated $76.1M as of September 30, 2025.

• Pro forma net tangible book value per share after IPO would be $7.39, with immediate dilution of $8.61 per share to new investors at the $16.00 midpoint price.

Use of proceeds and capital allocation

• Estimated net proceeds of $136.5M (or $157.4M if over-allotment is exercised) at $16.00 per share.

• Proceeds to fund clinical development of EVO756 (Phase 2/3 in CSU and AD), Phase 2 development of EVO301 in AD, and additional R&D, business development, and working capital.

• Combined with existing cash, expected to fund operations into the second half of 2028.